Custom service
ADA Testing Platform
Run anti-drug-antibody testing under a validated platform for your program
ADA Testing Platform supports programmes that run anti-drug-antibody testing under a validated platform for your program. In a typical engagement we plan the bridging ELISA platforms route first, confirm compatibility with cut-point statistical validation, and release validated ADA testing platform and run data on a 6–10 weeks setup schedule.
Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep bridging ELISA platforms as the primary option and hold cut-point statistical validation in reserve, so that scale-up never depends on an unproven step.
Preclinical and clinical ADA support
Platform transfer into client QC
Testing under full clinical CLIA certification
Samples requiring containment or licensing we do not hold (BSL-3, radioactive)
Analytical reports follow a fixed template: sample condition on receipt, method description with validation status, raw chromatograms and spectra, results with uncertainty, and an interpretation note. Urgent same-week slots are available for release-critical testing.
Service Highlights
- Bridging ELISA platforms as the default route, with cut-point statistical validation held as a proven fallback
- Sample analysis under GLP-style controls worked into the design where the application requires it
- Results are reported with detection limits and method validation status, so you know exactly what the number means
- Analytical confirmation of every intermediate before the final release
- Orthogonal methods are used by default — one measurement is an observation, two are data
- Validated ADA testing platform and run data delivered with a complete conjugation or synthesis certificate
How the work runs
Sample intake & plan
Samples are logged with chain of custody and the test matrix for ADA Testing Platform is confirmed.
Method selection
Analytical methods — bridging ELISA platforms, cut-point statistical validation — are chosen and their validation status documented.
Measurement
Testing is executed with system-suitability checks and orthogonal confirmation where required.
Data review
Chromatograms and spectra are reviewed by a second analyst before any result is issued.
Reporting
Validated ADA testing platform and run data is issued with detection limits and interpretation notes.
Follow-up support
We discuss anomalies and, where useful, propose the follow-up experiment that resolves them.
Specifications & timeline
- Turnaround
- 6–10 weeks setup
- Typical scale
- µg – g sample scale
- Chemistry options
- bridging ELISA platforms; cut-point statistical validation; sample analysis under GLP-style controls
- Deliverable
- Validated ADA testing platform and run data
- QC package
- Method report, raw data, validated result with detection limits
- Shipping
- Blue ice or ambient by material; chain-of-custody on receipt
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.